Neck Cancer With Unknown Primary Site Workup

  • Author: Philip E Zapanta, MD; Chief Editor: Arlen D Meyers, MD, MBA   more...
 
Updated: Sep 16, 2011
 

Laboratory Studies

  • Per anesthesia guidelines, routine labs (ECG, chemistries, CBC count, chest radiography) should be obtained in preparation for a panendoscopy and possible neck dissection in the operating room. Chemistries (eg, liver function tests [LFTs]) may also help to diagnose distant metastatic disease and to aid in the complete workup of staging the disease (TNM system).
  • In addition to general lab studies, serology positive for Epstein-Barr virus has been shown to correlate with the presence of nasopharyngeal carcinoma.[11, 12] However, the physical examination of the nasopharynx via endoscopy and directed biopsies of suspicious areas offers a higher yield.
  • More recently, a study was published that attempted to determine the site of the primary tumors by identifying HPV-related carcinomas via fine needle aspiration, both morphologically and by using in situ hybridization (ISH), in metastatic cervical lymph nodes. Nonkeratinizing morphology or HPV-positivity were highly predictive of oropharyngeal origin of the tumor.[13]
Next

Imaging Studies

  • Chest radiography (posteroanterior and lateral views)
    • This study allows the physician to screen for lung metastases from the occult primary malignancy or a concurrent primary lung neoplasm. Also, chest radiography helps in the complete staging of the disease process. If a suspicious lesion is found on chest radiograph, further investigation with a CT scan of the chest is warranted. Although no guidelines exist for screening for distant metastatic disease in advanced head and neck squamous cell carcinoma, recent studies had suggested that chest CTs were adequate screening tools for distant disease. Brouwer et al (2005) documented that the sensitivity and specificity was only 73% and 80%, respectively.[14] His group suggests that FDG-PET scans may be a better alternative.
    • If the results are consistent with metastases, the lesion obviates the need for surgical intervention and makes the patient a possible candidate for radiation/chemotherapy.
    • If the findings on the CT scan are consistent with a primary lung neoplasm, this represents either a synchronous primary malignancy or a source of the cervical metastases.
    • If a primary lung neoplasm is discovered, the patient's care should be shared with the appropriate oncologist.
  • CT scan of the head and neck with intravenous contrast
    • In terms of availability, cost effectiveness, quickness, and patient compliance, CT scanning is the imaging modality of choice for both the evaluation of cervical lymphadenopathy and the identification of occult primary lesions. Newer technology and methods of acquisition, such as the helical CT scanner, allows better image quality and resolution, better reconstructive capabilities, quicker scans, and decreased artifact. The quicker scans allow dynamic maneuvers to be used. The puffed cheek and modified Valsalva techniques can help open opposed mucosal surfaces in the oral cavity, oropharynx, and hypopharynx. This may allow the easier detection of unknown mucosal primaries.[15] Nonetheless, critical evaluation of the CT scan helps in the location of directed biopsies during panendoscopy in the workup of the unknown primary tumor.[3]
    • With respect to the evaluation of cervical lymphadenopathy, a CT scan of the neck is helpful in assessing the involvement of vital structures. It also provides the clinician with useful data regarding surgical resectability.
    • In addition to its usefulness in evaluating the clinically obvious neck mass, a CT scan, as seen in the image below, can be used to evaluate clinically negative cervical lymph node zones. Radiographic criteria of potential pathological lymph nodes include rounding of the lymph node, a size greater than 1.5 cm in the jugulodigastric region or greater than 1 cm in other regions, and a hypodense center of the lymph node that signifies necrosis. CT scan of neck with contrast. The arrows indicateCT scan of neck with contrast. The arrows indicate metastatic lymphadenopathy. Image courtesy of Head and Neck Cancer-Multidisciplinary Approach, Davidson, BJ.
  • MRI or magnetic resonance angiography of the head and neck
    • In the primary author's opinion, MRI is superior to CT scanning in anatomical detail and is helpful in iodine-allergic patients who need a contrast study. Unfortunately, MRI is slower than a CT acquisition and some patients may not be able to tolerate the physical constraints of the scanner.
    • MRI may be useful in the evaluation of the superior extent of metastatic cervical lymphadenopathy (ie, intracranial extension).
    • MRI may have a role in the preoperative workup of a patient with cancer of the head and neck once the primary site is known. The literature is limited in the use of current MRI technology (inversion recovery MRI, dynamic contrast enhanced MRI, MR spectroscopy, ultrasmall superparamagnetic iron oxide particles [USPIO], diffusion-weighted imaging) for the detection of the unknown primary; however, inversion recovery MRI has the best potential to identify the unknown primary. MRI is ideal for a patient with cancer on the base of the tongue or of the sinonasal tract.[15]
    • Although angiography is the criterion standard for evaluating the integrity of the great vessels, magnetic resonance angiography (MRA) is a less-invasive procedure and can provide useful information. This information can be used in the determination of resectability.[16]
  • Positron emission tomography imaging with 2-fluoro-2-deoxyglucose
    • Positron emission tomography (PET) is not typically used in the workup of occult primary tumors of the head and neck. With a radio-labeled glucose molecule, this imaging modality works on the assumption that areas of high metabolism pick up the tracer. Cancer cells have a high standard uptake value (SUV); in addition, areas of inflammation and infection also show signs of high metabolism.
    • Historically, this imaging modality is most often used after the workup for an unknown primary cancer is complete but has not yet revealed the primary site. At the primary author's institution, the PET scan is often used in the initial workup of an unknown primary tumor to help guide biopsies during panendoscopy. One study claimed a sensitivity and specificity rate of 100% and 94%, respectively, for PET, compared with conventional methods rates of 92% and 76%, respectively.[17] This is in contrast to a more recent study in which the PET sensitivity and specificity was 66% and 92.9%, respectively. The positive predictive and negative predictive values were 88.8% and 76.5%, respectively.[18] Depending on the situation, the authors often fuse the PET scan with a CT scan, as seen in the image below, to further delineate the lesions. Theoretically, a fused PET/CT can visualize lesions larger than 5 mm. CT/positron emission tomography (PET) fusion; areaCT/positron emission tomography (PET) fusion; areas of uptake on the PET scan are mapped to the CT scan, and this image depicts the primary lesion in the left floor of mouth with metastatic disease to level II.
    • Because of the limited access to PET imaging and the controversy regarding the mixed evidence of PET imaging in the detection of unknown primary cancers, it is not part of a standard workup.[19, 20] The use of fusing PET scans with CT scans for the workup of the unknown primary tumor is even further debated.[21] However, more recent evidence suggests that the combination of PET and panendoscopy detected 45.2% of unknown primary tumors of the head and neck.[18]
Previous
Next

Diagnostic Procedures

Fine-needle aspiration is the main diagnostic procedure in the workup of occult primary tumors of the head and neck. It is used to obtain a histological diagnosis of the presenting neck mass. The histology allows the clinician to narrow the differential diagnosis and to focus diagnostic and therapeutic treatment.

Previous
Next

Histologic Findings

Histologic appearance of metastatic squamous cell Histologic appearance of metastatic squamous cell carcinoma. Image courtesy of Atlas of Head and Neck Pathology, Wenig, BM.
Previous
 
 
Contributor Information and Disclosures
Author

Philip E Zapanta, MD  Assistant Professor of Surgery, Associate Director of Otolaryngology Residency Program in the Division of Otolaryngology-Head and Neck Surgery, Co-Director, Medical Education Fellowship, George Washington University Medical Center; Consulting Staff, Division of Otolaryngology-Head and Neck Surgery, Medical Faculty Associates

Philip E Zapanta, MD is a member of the following medical societies: American Academy of Otolaryngic Allergy, American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, Christian Medical & Dental Society, and Medical Society of the District of Columbia

Disclosure: Nothing to disclose.

Coauthor(s)

Guy J Petruzzelli, MD, PhD, MBA, FACS  The Charles Arthur Weaver Professor of Cancer Research, Professor and Senior Attending Physician, Director of Head, Neck, and Skull Base Surgery, Department of Otolaryngology, Rush University Medical Center

Guy J Petruzzelli, MD, PhD, MBA, FACS is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American Association for the Advancement of Science, American Association of Clinical Anatomists, American College of Surgeons, American Medical Association, American Society for Head and Neck Surgery, American Society of Clinical Oncology, Chicago Medical Society, North American Skull Base Society, Society of Surgical Oncology, Society of University Otolaryngologists-Head and Neck Surgeons, and Southwest Oncology Group

Disclosure: Nothing to disclose.

Ahmed Mohyeldin, PhD  George Washington University School of Medicine and Health Sciences, Washington, DC

Disclosure: Nothing to disclose.

Jeremy B White, MD  Resident Physician, Department of Plastic Surgery, Cleveland Clinic Florida

Jeremy B White, MD is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Benoit J Gosselin, MD, FRCSC  Associate Professor of Surgery, Dartmouth Medical School; Director, Comprehensive Head and Neck Oncology Program, Norris Cotton Cancer Center; Staff Otolaryngologist, Division of Otolaryngology-Head and Neck Surgery, Dartmouth-Hitchcock Medical Center

Benoit J Gosselin, MD, FRCSC is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American Head and Neck Society, American Medical Association, American Rhinologic Society, Canadian Medical Association, Canadian Society of Otolaryngology-Head & Neck Surgery, College of Physicians and Surgeons of Ontario, New Hampshire Medical Society, North American Skull Base Society, and Ontario Medical Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Nader Sadeghi, MD, FRCSC  Professor, Otolaryngology-Head and Neck Surgery, Director of Head and Neck Surgery, George Washington University School of Medicine and Health Sciences

Nader Sadeghi, MD, FRCSC is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American Head and Neck Society, American Thyroid Association, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Christopher L Slack, MD  Private Practice in Otolaryngology and Facial Plastic Surgery, Associated Coastal ENT; Medical Director, Treasure Coast Sleep Disorders

Christopher L Slack, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Medical Association

Disclosure: Nothing to disclose.

Chief Editor

Arlen D Meyers, MD, MBA  Professor, Department of Otolaryngology-Head and Neck Surgery, University of Colorado School of Medicine

Arlen D Meyers, MD, MBA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Head and Neck Society

Disclosure: Covidien Corp Consulting fee Consulting; US Tobacco Corporation Unrestricted gift Unknown; Axis Three Corporation Ownership interest Consulting; Omni Biosciences Ownership interest Consulting; Sentegra Ownership interest Board membership; Syndicom Ownership interest Consulting; Oxlo Consulting; Medvoy Ownership interest Management position; Cerescan Imaging Honoraria Consulting; GYRUS ACMI Honoraria Consulting

References
  1. Jereczek-Fossa BA, Jassem J, Orecchia R. Cervical lymph node metastases of squamous cell carcinoma from an unknown primary. Cancer Treat Rev. Apr 2004;30(2):153-64. [Medline].

  2. Wenig BM. Neoplasms of the nasal cavity and paranasal sinuses. In: Wenig BM, ed. Atlas of Head and Neck Pathology. Philadelphia: WB Saunders Co; 1993:29-39.

  3. Mendenhall WM, Mancuso AA, Parsons JT, Stringer SP, Cassisi NJ. Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Head Neck. Dec 1998;20(8):739-44. [Medline].

  4. Termine N, Panzarella V, Falaschini S, et al. HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988-2007). Ann Oncol. Oct 2008;19(10):1681-90. [Medline].

  5. Davidson BJ, Harter W, OMalley BB. Cervical lymph node metastasis from squamous cell carcinoma with unknown primary site. In: Harrison LB, Sessions RB, Hong WK, eds. Head and Neck Cancer-Multidisciplinary Approach. NY: Lippincott-Raven; 1999:391-410.

  6. Simo R, OConnell M. Metastatic squamous cell carcinoma of occult primary: beware the tonsillar remnant. J Laryngol Otol. Jun 2008;122(6):641-3. [Medline].

  7. Schmalbach CE, Miller FR. Occult primary head and neck carcinoma. Curr Oncol Rep. Mar 2007;9(2):139-46. [Medline].

  8. Savoury LW, Glckman JL. Cervical metastasis. In: Paparella MM, Shumrick DA, Myeroff WL, eds. Otolaryngology. 3rd ed. Philadelphia: WB Saunders Co; 1991:2565-2568.

  9. Robbins KT, Clayman G, Levine PA, et al. Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery. Arch Otolaryngol Head Neck Surg. Jul 2002;128(7):751-8. [Medline].

  10. DeSanto LW, Neel HB 3rd. Squamous cell carcinoma. Metastasis to the neck from an unknown or undiscovered primary. Otolaryngol Clin North Am. Aug 1985;18(3):505-13. [Medline].

  11. Neel HB 3rd, Pearson GR, Weiland LH, Taylor WF, Goepfert HH. Immunologic detection of occult primary cancer of the head and neck. Otolaryngol Head Neck Surg. Mar-Apr 1981;89(2):230-4. [Medline].

  12. Feinmesser R, Miyazaki I, Cheung R, Freeman JL, Noyek AM, Dosch HM. Diagnosis of nasopharyngeal carcinoma by DNA amplification of tissue obtained by fine-needle aspiration. N Engl J Med. Jan 2 1992;326(1):17-21. [Medline].

  13. Zhang MQ, El-Mofty SK, Davila RM. Detection of human papillomavirus-related squamous cell carcinoma cytologically and by in situ hybridization in fine-needle aspiration biopsies of cervical metastasis: a tool for identifying the site of an occult head and neck primary. Cancer. Apr 25 2008;114(2):118-23. [Medline].

  14. Brouwer J, de Bree R, Hoekstra OS, et al. Screening for distant metastases in patients with head and neck cancer: is chest computed tomography sufficient?. Laryngoscope. Oct 2005;115(10):1813-7. [Medline].

  15. McCabe KJ, Rubinstein D. Advances in head and neck imaging. Otolaryngol Clin North Am. Apr 2005;38(2):307-19, vii. [Medline].

  16. Dillon WP, Harnsberger HR. The impact of radiologic imaging on staging of cancer of the head and neck. Semin Oncol. Apr 1991;18(2):64-79. [Medline].

  17. Regelink G, Brouwer J, de Bree R. Detectin of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities. European Journal of Nuclear Medicine & Molecular Imaging. 2002;29:1024-30.

  18. Miller FR, Hussey D, Beeram M, Eng T, McGuff HS, Otto RA. Positron emission tomography in the management of unknown primary head and neck carcinoma. Arch Otolaryngol Head Neck Surg. Jul 2005;131(7):626-9. [Medline].

  19. Jungehulsing M, Scheidhauer K, Damm M, et al. 2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head Neck Surg. Sep 2000;123(3):294-301. [Medline].

  20. Greven KM, Keyes JW Jr, Williams DW 3rd, McGuirt WF, Joyce WT 3rd. Occult primary tumors of the head and neck: lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose. Cancer. Jul 1 1999;86(1):114-8. [Medline].

  21. Zanation AM, Sutton DK, Couch ME, Weissler MC, Shockley WW, Shores CG. Use, accuracy, and implications for patient management of [18F]-2-fluorodeoxyglucose-positron emission/computerized tomography for head and neck tumors. Laryngoscope. Jul 2005;115(7):1186-90. [Medline].

  22. Jesse RH, Perez CA, Fletcher GH. Cervical lymph node metastasis: unknown primary cancer. Cancer. Apr 1973;31(4):854-9. [Medline].

  23. Grau C, Johansen LV, Jakobsen J, Geertsen P, Andersen E, Jensen BB. Cervical lymph node metastases from unknown primary tumours. Results from a national survey by the Danish Society for Head and Neck Oncology. Radiother Oncol. May 2000;55(2):121-9. [Medline].

  24. Maulard C, Housset M, Brunel P, et al. Postoperative radiation therapy for cervical lymph node metastases from an occult squamous cell carcinoma. Laryngoscope. Aug 1992;102(8):884-90. [Medline].

  25. Argiris A, Smith SM, Stenson K, et al. Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary. Ann Oncol. Aug 2003;14(8):1306-11. [Medline].

  26. Sher DJ, Balboni TA, Haddad RI, et al. Efficacy and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown primary of head and neck. Int J Radiat Oncol Biol Phys. Aug 1 2011;80(5):1405-11. [Medline].

  27. Chen AM, Farwell DG, Lau DH, Li BQ, Luu Q, Donald PJ. Radiation Therapy in the Management of Head-and-Neck Cancer of Unknown Primary Origin: How Does the Addition of Concurrent Chemotherapy Affect the Therapeutic Ratio?. Int J Radiat Oncol Biol Phys. Oct 1 2011;81(2):346-52. [Medline].

  28. Randall DA, Johnstone PA, Foss RD, Martin PJ. Tonsillectomy in diagnosis of the unknown primary tumor of the head and neck. Otolaryngol Head Neck Surg. Jan 2000;122(1):52-5. [Medline].

  29. Kothari P, Randhawa PS, Farrell R. Role of tonsillectomy in the search for a squamous cell carcinoma from an unknown primary in the head and neck. Br J Oral Maxillofac Surg. Jun 2008;46(4):283-7. [Medline].

  30. Huang CC, Tseng FY, Yeh TH, et al. Prognostic factors of unknown primary head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. Sep 2008;139(3):429-35. [Medline].

  31. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. Apr 1998;16(4):1310-7. [Medline].

  32. de Braud F, al-Sarraf M. Diagnosis and management of squamous cell carcinoma of unknown primary tumor site of the neck. Semin Oncol. Jun 1993;20(3):273-8. [Medline].

  33. Koch WM, Bhatti N, Williams MF, Eisele DW. Oncologic rationale for bilateral tonsillectomy in head and neck squamous cell carcinoma of unknown primary source. Otolaryngol Head Neck Surg. Mar 2001;124(3):331-3. [Medline].

  34. Miller FR, Karnad AB, Eng T, Hussey DH, Stan McGuff H, Otto RA. Management of the unknown primary carcinoma: long-term follow-up on a negative PET scan and negative panendoscopy. Head Neck. Jan 2008;30(1):28-34. [Medline].

  35. Cancer of the Unknown Primary Site. In: Petruzzelli GJ. Practical Head and Neck Oncology. San Diego: Plural Publications; 2009:385-412.

Previous
Next
 
CT scan of neck with contrast. The arrows indicate metastatic lymphadenopathy. Image courtesy of Head and Neck Cancer-Multidisciplinary Approach, Davidson, BJ.
CT/positron emission tomography (PET) fusion; areas of uptake on the PET scan are mapped to the CT scan, and this image depicts the primary lesion in the left floor of mouth with metastatic disease to level II.
Histologic appearance of metastatic squamous cell carcinoma. Image courtesy of Atlas of Head and Neck Pathology, Wenig, BM.
Table. Possible Source of Unknown Primary Cancer Based on Symptoms
SymptomPossible Source
Otalgia/aural fullnessPharynx, larynx, nasopharynx, or ear
Dysphagia/odynophagiaPharynx, esophagus, or oral cavity
HoarsenessLarynx
Trismus, dysarthriaOral cavity or oropharynx
Nasal congestion, epistaxisSinonasal tract
AspirationOropharynx or larynx
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.